thioguanine

(redirected from 6-thioguanine)
Also found in: Dictionary, Thesaurus, Acronyms.

thioguanine

 [thi″o-gwah´nēn]
a guanine analogue in which sulfur replaces the oxygen atom of guanine; used as an antineoplastic agent almost exclusively in the treatment of acute myelogenous leukemia and acute lymphoblastic leukemia. Called also 6-thioguanine and 6-TG.

thioguanine

/thio·gua·nine/ (-gwah´nēn) an antineoplastic derived from mercaptopurine; used in the treatment of acute myelogenous leukemia.

thioguanine

[thī′ōgwä′nēn]
a purine analog antagonist, an antineoplastic that acts as an antimetabolite.
indications It is prescribed in the treatment of a variety of malignant neoplastic diseases, especially acute and chronic myelogenous leukemias.
contraindications Known hypersensitivity or resistance to this drug prohibits its use. It is not given during pregnancy.
adverse effects Among the most serious adverse effects are bone marrow depression, GI distress, and stomatitis.

thioguanine

Lanvis® Oncology An antimitotic purine analogue, used against AML. See Purine.

thioguanine

Tioguanine, a drug used in the treatment of acute myeloblastic leukaemia. A brand name is Lanvis.

thioguanine

an antineoplastic (2-aminopurine-6-thiol) used in the treatment of leukemia.
References in periodicals archive ?
6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease.
6-MP is converted nonenzymatically to 6-thioguanine (6-TGN), the biologically active metabolite responsible for the therapeutic response.
A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising: (a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and (b) determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder, wherein the level of 6-thioguanine less than about 230 pmol per 8x[10.
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial.
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
It's unnecessary to routinely monitor 6-thioguanine nucleotide (6-TGN), the active metabolite of azathioprine and 6-MP.
TPMT assay methodology is poorly standardized, but our results should apply equally to the respective cutoff activities of other assays; for example, when 6-thioguanine is used as substrate.
6-MP is activated to 6-thioinosine monophosphate (6-TIMP) and subsequently to 6-thioguanine (6-TG) nucleotides (6-TGNs) by a multistep process involving several enzymes of the purine salvage pathway (2).
Reagents and media for cell culture were obtained from the following suppliers: 6-thioguanine (TG), citric acid, and dimethyl sulfoxide (DMSO) were obtained from Sigma (St.
Although the physiologic function of the enzyme is still unknown, TPMT is involved in the metabolism of the thiopurine drugs 6-mercaptopurine, 6-thioguanine, and azathioprine.
The thiopurines 6-mercaptopurine (Purinethol[R]), azathioprine (Imurel[R]), and 6-thioguanine (Lanvis[R]) are used in the treatment of leukemia and inflammatory bowel disease (IBD) (4) and to prevent organ transplant rejection (1-3).
The enzyme catalyzes the S-methylation of these medicinal agents, a metabolic pathway that competes with the formation of pharmacologically active 6-thioguanine nucleotides (6-TGNs), thereby modulating their therapeutic and toxic effects (1,2).